Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive...

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Current Alzheimer's disease (AD) immunotherapy strategies assume human amyloid beta protein (Abeta) can be targeted like animal or synthetic forms.
• Abeta structure varies by source and cofactors, necessitating investigation into human-derived Abeta's effects on brain function.
• The potential for antibody-mediated prevention of Abeta-induced neurological impairment requires examination.

Purpose of the Study:

• To determine if human-derived oligomeric Abeta species impair brain function.
• To investigate whether antibodies can prevent the disruptive effects of human Abeta oligomers.
• To assess the therapeutic potential of targeting soluble Abeta oligomers in early AD.

Main Methods:

• Ex vivo analysis of human cerebrospinal fluid (CSF) containing Abeta dimers and monomers.
• In vivo assessment of hippocampal long-term potentiation (LTP) in response to human Abeta species.
• Administration of an anti-Abeta monoclonal antibody to evaluate its preventative effects on synaptic plasticity disruption.

Main Results:

• Untreated human CSF containing Abeta dimers rapidly inhibited hippocampal LTP in vivo.
• Abeta monomer isolated from human CSF did not affect long-term potentiation.
• Acute systemic infusion of an anti-Abeta monoclonal antibody successfully prevented Abeta dimer-induced disruption of synaptic plasticity.

Conclusions:

• Soluble Abeta oligomers, specifically dimers derived from human CSF, impair synaptic plasticity.
• Passive immunization targeting soluble Abeta oligomers represents a promising therapeutic strategy for early Alzheimer's disease.
• Antibody-based interventions can effectively prevent the detrimental effects of human Abeta species on brain function.